Scribe Therapeutics starts first human trial for cholesterol-lowering gene therapy
Scribe Therapeutics reported second-quarter 2026 financial results and pipeline progress. The company initiated a first-in-human phase 1 clinical trial of STX-1150 in Australia in mid-2026, according to the company, and presented late-breaking non-human primate data at the European Atherosclerosis S
<p>Scribe Therapeutics reported second-quarter 2026 financial results and pipeline progress. The company initiated a first-in-human phase 1 clinical trial of STX-1150 in Australia in mid-2026, according to the company, and presented late-breaking non-human primate data at the European Atherosclerosis S</p>